These peptide vaccines are composed of citrullinated peptides from vimentin and enolase that are known targets of ACPAs in RA.21,22 We hypothesize that there may be many more PAD4 substrates at the cell surface that can be identified and potentially leveraged for similar anti-tumor purposes. The gene discussed is PADI4; the disease is rheumatoid arthritis.